DESLORATADINE TABLETS
Land: Kanada
Språk: engelska
Källa: Health Canada
Produktens egenskaper
(SPC)
17-10-2018
Vissa dokument för denna produkt är för närvarande inte tillgängliga, du kan skicka en begäran till vår kundservice och vi kommer att meddela dig så snart vi kan få dem.
Skicka förfrågan.
Skicka förfrågan.
Aktiva substanser:
DESLORATADINE
Tillgänglig från:
APOTEX INC
ATC-kod:
R06AX27
INN (International namn):
DESLORATADINE
Dos:
5MG
Läkemedelsform:
TABLET
Sammansättning:
DESLORATADINE 5MG
Administreringssätt:
ORAL
Enheter i paketet:
10/12/20/24/30/36/48/50
Receptbelagda typ:
OTC
Terapiområde:
SECOND GENERATION ANTIHISTAMINES
Produktsammanfattning:
Active ingredient group (AIG) number: 0143961001; AHFS:
Bemyndigande status:
APPROVED
Tillstånd datum:
2010-02-05
Produktens egenskaper
Page 1 of 35
PRODUCT MONOGRAPH
DESLORATADINE TABLETS 5 MG DESLORATADINE
HISTAMINE H
1
-RECEPTOR ANTAGONIST
APOTEX INC.
DATE OF REVISION:
150 SIGNET DRIVE
OCTOBER 17, 2018
TORONTO, ONTARIO
M9L 1T9
CONTROL NUMBER: 220366
Page 2 of 35
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
........................................................ 3
SUMMARY
PRODUCT
INFORMATION
................................................................................
3
INDICATIONS
AND
CLINICAL
USE
......................................................................................
3
CONTRAINDICATIONS
...........................................................................................................
3
WARNINGS
AND
PRECAUTIONS
..........................................................................................
3
ADVERSE
REACTIONS
...........................................................................................................
5
DRUG
INTERACTIONS
............................................................................................................
6
DOSAGE
AND
ADMINISTRATION
........................................................................................
7
OVERDOSAGE
..........................................................................................................................
7
ACTION
AND
CLINICAL
PHARMACOLOGY
.......................................................................
7
STORAGE
AND
STABILITY
..................................................................................................
10
SPECIAL
HANDLING
INSTRUCTIONS
...............................................................................
10
DOSAGE
FORMS,
COMPOSITION
AND
PACKAGING ...................................................... 10
PART II: SCIENTIFIC INFORMATION
...............................................................................
12
PHARMACEUTICAL
INFORMATION
.................................................................................
12
CLINICAL
TRIALS
.............................
Läs hela dokumentet
